Evidence map›Paper›PMID 31992639›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Histamine receptor agonist alleviates severe cardiorenal damages by eliciting anti-inflammatory programming.

Kazuyuki Noguchi, Junji Ishida, Jun-Dal Kim, Naoto Muromachi, Koichiro Kako, Hayase Mizukami, Weizhe Lu, Tomohiro Ishimaru, Shohei Kawasaki, Shuzo Kaneko and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Histamine regulates the activity and the expression of the NaInflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  4. Article
  5. Article
  6. Recovery of the histamine HScientific reports · 2023
    Article
  7. Article
  8. Histamine receptors in heart failure.Heart failure reviews · 2022
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Histamine and histidine decarboxylase: Immunomodulatory functions and regulatory mechanisms.Genes to cells : devoted to molecular & cellular mechanisms · 2020
    Review
  14. Histamine provides an original vista on cardiorenal syndrome.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Kazuyuki NoguchiLife Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance, University of Tsukuba, Ibaraki, 305-8577 Tsukuba, Japan.ORCID 0000-0003-4904-5042
Junji IshidaLife Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance, University of Tsukuba, Ibaraki, 305-8577 Tsukuba, Japan.
Jun-Dal KimLife Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance, University of Tsukuba, Ibaraki, 305-8577 Tsukuba, Japan.
Naoto MuromachiMaster's Program in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
Koichiro KakoFaculty of Life and Environmental Sciences, University of Tsukuba, Ibaraki 305-8572 Tsukuba, Japan.
Hayase MizukamiGraduate School of Life and Environmental Sciences, University of Tsukuba, Ibaraki 305-8572 Tsukuba, Japan.
Weizhe LuLife Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance, University of Tsukuba, Ibaraki, 305-8577 Tsukuba, Japan.
Tomohiro IshimaruGraduate School of Life and Environmental Sciences, University of Tsukuba, Ibaraki 305-8572 Tsukuba, Japan.
Shohei KawasakiGraduate School of Life and Environmental Sciences, University of Tsukuba, Ibaraki 305-8572 Tsukuba, Japan.
Shuzo KanekoDepartment of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575 Tsukuba, Japan.ORCID 0000-0002-8613-6499
Joichi UsuiDepartment of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575 Tsukuba, Japan.ORCID 0000-0002-6709-4000
Hiroshi OhtsuDepartment of Engineering, School of Medicine, Tohoku University, Aoba-ku, 980-8775 Sendai, Japan.
Kunihiro YamagataDepartment of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575 Tsukuba, Japan.
Akiyoshi FukamizuLife Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance, University of Tsukuba, Ibaraki, 305-8577 Tsukuba, Japan; akif@tara.tsukuba.ac.jp.
University of Tsukuba · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure and chronic kidney disease are major causes of morbidity and mortality internationally. Although these dysfunctions are common and frequently coexist, the factors involved in their relationship in cardiorenal regulation are still largely unknown, mainly due to a lack of detailed molecular targets. Here, we found the increased plasma histamine in a preclinical mouse model of severe cardiac dysfunction, that had been cotreated with angiotensin II (Ang II), nephrectomy, and salt (ANS). The ANS mice exhibited impaired renal function accompanied with heart failure, and histamine depletion, by the genetic inactivation of histidine decarboxylase in mice, exacerbated the ANS-induced cardiac and renal abnormalities, including the reduction of left ventricular fractional shortening and renal glomerular and tubular injuries. Interestingly, while the pharmacological inhibition of the histamine receptor H3 facilitated heart failure and kidney injury in ANS mice, administration of the H3 agonist immethridine (Imm) was protective against cardiorenal damages. Transcriptome analysis of the kidney and biochemical examinations using blood samples illustrated that the increased inflammation in ANS mice was alleviated by Imm. Our results extend the pharmacological use of H3 agonists beyond the initial purposes of its drug development for neurogenerative diseases and have implications for therapeutic potential of H3 agonists that invoke the anti-inflammatory gene expression programming against cardiorenal damages.

Indexed as

AnimalsAnti-Inflammatory AgentsDisease Models, AnimalHeartHeart FailureHistamineHistamine AgonistsKidneyKidney DiseasesMiceProtective AgentsReceptors, Histamine H3Anti-Inflammatory AgentsHistamineHistamine AgonistsProtective AgentsReceptors, Histamine H3animal modelanti-inflammationcardiorenal damagesH3 agonisthistamine

Identifiers

PMID31992639
PMCPMC7022214
OpenAlexW3003643337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.